A suitable medication would have been a DDP-4 inhibitor, glitazone, or sulfonylurea. The use of GLP-1 receptor agonists is not appropriate, as it is only recommended when triple therapy with metformin and two other oral drugs has failed.

NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022, reflecting advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. The first-line drug of choice remains metformin, which should be titrated up slowly to minimize gastrointestinal upset. HbA1c targets should be agreed upon with patients and checked every 3-6 months until stable, with consideration for relaxing targets on a case-by-case basis. Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates and controlling intake of foods containing saturated fats and trans fatty acids. Blood pressure targets are the same as for patients without type 2 diabetes, and antiplatelets should not be offered unless a patient has existing cardiovascular disease. Only patients with a 10-year cardiovascular risk > 10% should be offered a statin, with atorvastatin 20mg as the first-line choice.

Treatment Options for Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a liver disease that can lead to cirrhosis if left untreated. Ursodeoxycholic acid (UDCA) is the main treatment for PBC, as it can prevent or delay the development of cirrhosis. UDCA increases bile flow, inhibits toxic bile acid production, prevents hepatocyte apoptosis, and reduces the liver’s immune response. However, UDCA may cause side effects such as diarrhea, nausea, and thinning hair.

Spironolactone is a diuretic that can be useful for end-stage liver disease with ascites, but it is not indicated for treating fatigue in PBC patients. Aspirin and ibuprofen should be avoided by PBC patients, as they can worsen liver disease. Cholestyramine is used for cholestatic itching, but it should not be taken with UDCA as it can prevent UDCA absorption.

In summary, UDCA is the primary treatment for PBC, and other medications should be used with caution and only for specific symptoms or complications.

Patients who have ascites due to liver cirrhosis should receive an aldosterone antagonist, such as spironolactone, as it helps to counteract the secondary hyperaldosteronism that occurs in cirrhosis. This condition attempts to increase intravascular volume, which is lost into the abdomen as ascites. Amiloride is not effective in treating ascites as it does not lead to significant diuresis and has no effect on the aldosterone pathway. Eplerenone is an alternative to spironolactone for patients who cannot tolerate its adverse effects. Furosemide is useful in treating ascites but should be used in conjunction with spironolactone due to the additional benefits of aldosterone blocking. Bendroflumethiazide is not useful in managing or preventing fluid overload conditions such as ascites.

Understanding Ascites: Causes and Management

Ascites is a medical condition characterized by the accumulation of abnormal fluid in the abdomen. The causes of ascites can be classified into two groups based on the serum-ascites albumin gradient (SAAG) level. A SAAG level greater than 11g/L indicates portal hypertension, which is commonly caused by liver disorders such as cirrhosis, alcoholic liver disease, and liver metastases. On the other hand, a SAAG level less than 11g/L is caused by hypoalbuminaemia, malignancy, infections, and other factors such as bowel obstruction and biliary ascites.

The management of ascites involves reducing dietary sodium and fluid restriction, especially if the sodium level is less than 125 mmol/L. Aldosterone antagonists like spironolactone and loop diuretics are often prescribed to patients. In some cases, drainage through therapeutic abdominal paracentesis is necessary. Large-volume paracentesis requires albumin cover to reduce the risk of paracentesis-induced circulatory dysfunction and mortality. Prophylactic antibiotics are also recommended to prevent spontaneous bacterial peritonitis. In severe cases, a transjugular intrahepatic portosystemic shunt (TIPS) may be considered.

Understanding the causes and management of ascites is crucial in providing appropriate medical care to patients. Proper diagnosis and treatment can help alleviate symptoms and improve the patient’s quality of life.

CA 19-9 and Pancreatic Cancer

Understanding Tumour Markers

Tumour markers are substances that can be found in the blood, urine, or tissues of people with cancer. They are often used to help diagnose and monitor cancer, as well as to determine the effectiveness of treatment. Tumour markers can be divided into different categories, including monoclonal antibodies against carbohydrate or glycoprotein tumour antigens, tumour antigens, enzymes, and hormones.

Monoclonal antibodies are used to target specific tumour antigens, which are proteins or other molecules that are found on the surface of cancer cells. Some common tumour markers include CA 125 for ovarian cancer, CA 19-9 for pancreatic cancer, and CA 15-3 for breast cancer. However, it is important to note that tumour markers usually have a low specificity, meaning that they can also be found in people without cancer.

Tumour antigens are proteins that are produced by cancer cells and can be detected in the blood or tissues of people with cancer. Some examples of tumour antigens include prostate specific antigen (PSA) for prostatic carcinoma, alpha-feto protein (AFP) for hepatocellular carcinoma and teratoma, and carcinoembryonic antigen (CEA) for colorectal cancer.

Enzymes and hormones can also be used as tumour markers. For example, alkaline phosphatase and neurone specific enolase are enzymes that can be elevated in people with cancer, while hormones such as calcitonin and ADH can be used to detect certain types of cancer.

In summary, tumour markers are an important tool in the diagnosis and monitoring of cancer. However, they should be used in conjunction with other diagnostic tests and imaging studies, as they are not always specific to cancer and can also be elevated in people without cancer.

To calculate alcohol units, multiply the volume in milliliters by the alcohol by volume (ABV) and divide by 1,000.

Alcohol consumption guidelines were revised in 2016 by the Chief Medical Officer, based on recommendations from an expert group report. The most significant change was a reduction in the recommended maximum number of units of alcohol for men from 21 to 14, aligning with the guidelines for women. The government now advises that both men and women should not exceed 14 units of alcohol per week, and if they do, it is best to spread it evenly over three or more days. Pregnant women are advised not to drink alcohol at all, as it can cause long-term harm to the baby. One unit of alcohol is equivalent to 10 mL of pure ethanol, and the strength of a drink is determined by its alcohol by volume (ABV). Examples of one unit of alcohol include a 25ml single measure of spirits with an ABV of 40%, a third of a pint of beer with an ABV of 5-6%, and half a 175ml standard glass of red wine with an ABV of 12%. To calculate the number of units in a drink, multiply the number of millilitres by the ABV and divide by 1,000.

A femoral hernia can lead to the serious complication of strangulation. In this case, the patient has a non-reducible mass located below the pubic tubercle, which is typical of a femoral hernia. However, the accompanying symptoms of vomiting, bloody stools, and a toxic appearance suggest that the hernia has become strangulated, meaning that the blood supply to the herniated tissue has been compromised and may lead to tissue death.

An incarcerated femoral hernia would also present as a non-reducible mass below the pubic tubercle, but without the symptoms of strangulation.

In contrast, an incarcerated inguinal hernia would present as a non-reducible mass above and towards the middle of the pubic tubercle, and would not cause symptoms of strangulation.

A perforated peptic ulcer would cause pain in the upper abdomen, syncope, and possibly vomiting blood, which is different from the patient’s symptoms.

Similarly, a strangulated inguinal hernia would cause similar symptoms, but the mass would be located above and towards the middle of the pubic tubercle, rather than below it.

Understanding Femoral Hernias

Femoral hernias occur when a part of the bowel or other abdominal organs pass through the femoral canal, which is a potential space in the anterior thigh. This can result in a lump in the groin area that is mildly painful and typically non-reducible. Femoral hernias are less common than inguinal hernias, accounting for only 5% of abdominal hernias, and are more prevalent in women, especially those who have had multiple pregnancies. Diagnosis is usually clinical, but ultrasound may be used to confirm the presence of a femoral hernia and exclude other possible causes of a lump in the groin area.

Complications of femoral hernias include incarceration, where the herniated tissue cannot be reduced, and strangulation, which is a surgical emergency. The risk of strangulation is higher with femoral hernias than with inguinal hernias and increases over time. Bowel obstruction and bowel ischaemia may also occur, leading to significant morbidity and mortality for the patient.

Surgical repair is necessary for femoral hernias, and it can be done laparoscopically or via a laparotomy. Hernia support belts or trusses should not be used for femoral hernias due to the risk of strangulation. In an emergency situation, a laparotomy may be the only option. It is essential to distinguish femoral hernias from inguinal hernias, as they have different locations and require different management approaches.

Hepatocellular carcinoma is primarily caused by hepatitis B worldwide, while in Europe, hepatitis C is the most common cause.

Hepatocellular carcinoma (HCC) is a type of cancer that ranks as the third most common cause of cancer worldwide. The leading cause of HCC globally is chronic hepatitis B, while chronic hepatitis C is the most common cause in Europe. The primary risk factor for developing HCC is liver cirrhosis, which can result from various factors such as hepatitis B and C, alcohol, haemochromatosis, and primary biliary cirrhosis. Other risk factors include alpha-1 antitrypsin deficiency, hereditary tyrosinosis, glycogen storage disease, aflatoxin, certain drugs, porphyria cutanea tarda, male sex, diabetes mellitus, and metabolic syndrome.

HCC tends to present late, and patients may exhibit features of liver cirrhosis or failure such as jaundice, ascites, RUQ pain, hepatomegaly, pruritus, and splenomegaly. In some cases, decompensation may occur in patients with chronic liver disease. Raised AFP levels are also common. Screening with ultrasound and alpha-fetoprotein may be necessary for high-risk groups, including patients with liver cirrhosis secondary to hepatitis B and C or haemochromatosis, and men with liver cirrhosis secondary to alcohol.

Management options for early-stage HCC include surgical resection, liver transplantation, radiofrequency ablation, transarterial chemoembolisation, and sorafenib, a multikinase inhibitor. It is important to note that Wilson’s disease is an exception to the typical causes of liver cirrhosis and HCC.

For cases of anal fissures that do not respond to conservative management, sphincterotomy may be considered as the next step. This is likely the case for the patient in question, who has not seen improvement with laxatives, lubricants, and topical GTN. While a high-fibre diet is important in managing anal fissures, it should be initiated alongside other conservative measures. If the patient had a perianal abscess, incision and drainage would be the appropriate treatment. For haemorrhoids, rubber band ligation would be the management, while anal fistulae would require seton insertion.

Understanding Anal Fissures: Causes, Symptoms, and Treatment

Anal fissures are tears in the lining of the distal anal canal that can be either acute or chronic. Acute fissures last for less than six weeks, while chronic fissures persist for more than six weeks. The most common risk factors for anal fissures include constipation, inflammatory bowel disease, and sexually transmitted infections such as HIV, syphilis, and herpes.

Symptoms of anal fissures include painful, bright red rectal bleeding, with around 90% of fissures occurring on the posterior midline. If fissures are found in other locations, underlying causes such as Crohn’s disease should be considered.

Management of acute anal fissures involves softening stool, dietary advice, bulk-forming laxatives, lubricants, topical anaesthetics, and analgesia. For chronic anal fissures, the same techniques should be continued, and topical glyceryl trinitrate (GTN) is the first-line treatment. If GTN is not effective after eight weeks, surgery (sphincterotomy) or botulinum toxin may be considered, and referral to secondary care is recommended.

In summary, anal fissures can be a painful and uncomfortable condition, but with proper management, they can be effectively treated. It is important to identify and address underlying risk factors to prevent the development of chronic fissures.

Understanding Alcoholic Liver Disease and its Management

Alcoholic liver disease is a range of conditions that includes alcoholic fatty liver disease, alcoholic hepatitis, and cirrhosis. One of the characteristic findings in this disease is an elevated gamma-GT level. Additionally, a ratio of AST:ALT greater than 2, and especially greater than 3, strongly suggests acute alcoholic hepatitis.

When it comes to managing alcoholic hepatitis, glucocorticoids such as prednisolone are often used during acute episodes. The Maddrey’s discriminant function (DF) is used to determine who would benefit from glucocorticoid therapy. This function is calculated using prothrombin time and bilirubin concentration. Pentoxyphylline is also sometimes used as a treatment option.

A study called STOPAH compared the two common treatments for alcoholic hepatitis, pentoxyphylline and prednisolone. The study showed that prednisolone improved survival at 28 days, while pentoxyphylline did not improve outcomes. Understanding the different types of alcoholic liver disease and their management options is crucial for healthcare professionals in providing effective care for patients.

Understanding Geographic Tongue: Symptoms, Causes, and Management

Geographic tongue is a common and benign condition that affects the tongue. It is characterized by irregular, smooth, red patches with a white border that resemble a map. While some individuals may experience pain or discomfort, others may not have any symptoms at all. The cause of geographic tongue is unknown, and there is currently no cure. However, symptomatic pain relief and avoidance of certain triggers may help manage the condition.

It is important to differentiate geographic tongue from other oral conditions such as oral candidiasis, oral leukoplakia, and vitamin deficiencies. Oral candidiasis can present with white/yellow plaques that can be easily removed, while oral leukoplakia presents with painless white plaques that cannot be easily scraped away and may be pre-malignant. Vitamin deficiencies such as B12 and C can also cause oral symptoms.

Overall, geographic tongue is a harmless condition that primarily affects females. While it may cause discomfort for some individuals, it does not pose any serious health risks. If you are experiencing symptoms of geographic tongue, it is recommended to seek advice from a healthcare professional for proper diagnosis and management.

Cyclical Vomiting Syndrome is characterized by severe nausea and vomiting that occurs in distinct episodes lasting from a few hours to a few days. This condition is often associated with migraine and may also result in reduced appetite and weight loss. Unlike Crohn’s disease, which typically presents with diarrhea, abdominal pain, and weight loss, Cyclical Vomiting Syndrome does not involve these symptoms. While nausea and weight loss may be present in Pheochromocytoma, this condition does not typically involve discrete episodes of vomiting. Symptoms such as headaches, tremors, palpitations, and anxiety may also be present in Pheochromocytoma. The episodes of vomiting in Cyclical Vomiting Syndrome are not related to food consumption, making bulimia an unlikely diagnosis.

Understanding Cyclical Vomiting Syndrome

Cyclical vomiting syndrome is a rare condition that is more commonly seen in children than adults. It affects females slightly more than males, and its cause is unknown. However, 80% of children and 25% of adults who develop CVS also have migraines. The condition is characterized by severe nausea and sudden vomiting that can last for hours to days. Patients may experience intense sweating and nausea before an episode, but they are typically well in between episodes. Other symptoms that may be present include weight loss, reduced appetite, abdominal pain, diarrhea, dizziness, photophobia, and headache.

To diagnose CVS, doctors typically perform routine blood tests to exclude any underlying conditions. A pregnancy test may also be considered in women. Treatment for CVS involves avoiding triggers and using prophylactic medications such as amitriptyline, propranolol, and topiramate. During acute episodes, ondansetron, prochlorperazine, and triptans may be used.

Overall, understanding cyclical vomiting syndrome is important for patients and healthcare providers alike. By recognizing the symptoms and seeking appropriate treatment, patients can manage their condition and improve their quality of life.

Antihistamines, specifically cyclizine, are the recommended first-line treatment for nausea and vomiting in pregnancy, including hyperemesis gravidarum. Dexamethasone is not typically used for hyperemesis gravidarum, as it is more commonly used for post-operative and chemotherapy-induced nausea and vomiting. Domperidone is not commonly used for hyperemesis gravidarum, as it is primarily used to treat nausea in patients with Parkinson’s disease. Metoclopramide is a second-line treatment option for hyperemesis gravidarum, but is not the first-line choice.

Hyperemesis gravidarum is an extreme form of nausea and vomiting of pregnancy that occurs in around 1% of pregnancies and is most common between 8 and 12 weeks. It is associated with raised beta hCG levels and can be caused by multiple pregnancies, trophoblastic disease, hyperthyroidism, nulliparity, and obesity. Referral criteria for nausea and vomiting in pregnancy include continued symptoms with ketonuria and/or weight loss, a confirmed or suspected comorbidity, and inability to keep down liquids or oral antiemetics. The diagnosis of hyperemesis gravidarum requires the presence of 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance. Management includes first-line use of antihistamines and oral cyclizine or promethazine, with second-line options of ondansetron and metoclopramide. Admission may be needed for IV hydration. Complications can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth issues.

Treatment and Diagnosis of Acute Pancreatitis

Acute pancreatitis can lead to systemic inflammatory response syndrome and multiple organ dysfunction syndromes. The mainstay of treatment is supportive measures such as fluid resuscitation and oxygen supplementation. Abdominal ultrasound can be useful to identify gallstones as the cause of pancreatitis, but fluid resuscitation takes priority. IV antibiotics are not indicated unless complications occur. Enteral feeding is preferred over nil by mouth, and parenteral feeding should be considered if enteral feeding is not tolerated. Urgent CT of the abdomen is not necessary in the acute stage unless complications are suspected. However, for severe pancreatitis, contrast-enhanced CT may be indicated four days after initial symptoms to assess for complications.

Differential Diagnosis of Liver Disorders in Pregnancy

Intrahepatic cholestasis of pregnancy (ICP), hyperemesis gravidarum, cholecystitis, acute fatty liver of pregnancy (AFLP), and HELLP syndrome are all potential liver disorders that can occur during pregnancy.

ICP is the most common pregnancy-related liver disorder and is characterised by generalised itching, jaundice, and elevated total serum bile acid levels. Maternal outcomes are good, but fetal outcomes can be devastating.

Hyperemesis gravidarum is characterised by persistent nausea and vomiting associated with ketosis and weight loss. Elevated transaminase levels may occur, but significantly elevated liver enzymes would suggest an alternative aetiology.

Cholecystitis is inflammation of the gall bladder that occurs most commonly due to gallstones. The most common presenting symptom is upper abdominal pain, which localises to the right upper quadrant.

AFLP is characterised by microvesicular steatosis in the liver and can present with malaise, nausea and vomiting, right upper quadrant and epigastric pain, and acute renal failure. Both AST and ALT levels can be elevated, and hypoglycaemia is common.

HELLP syndrome is a life-threatening condition that can potentially complicate pregnancy and is characterised by haemolysis, elevated liver enzyme levels, and low platelet levels. Symptoms are non-specific and include malaise, nausea and vomiting, and weight gain. A normal platelet count and no evidence of haemolysis are not consistent with a diagnosis of HELLP syndrome.

Early recognition, treatment, and timely delivery are imperative for all of these liver disorders in pregnancy.

If a person with Addison’s disease experiences vomiting, they should take IM hydrocortisone until the vomiting stops. This is especially important if the vomiting is caused by food poisoning from undercooked meat. IM hydrocortisone is a glucocorticoid steroid hormone that is used to manage Addison’s disease and prevent an Addisonian crisis. It is important to note that doubling the fludrocortisone dose or pausing hydrocortisone is not the correct approach in this situation. The patient requires extra hydrocortisone to prevent an Addisonian crisis, not extra fludrocortisone. While drinking plenty of fluids is generally good advice for someone who is vomiting, it is not sufficient for a person with Addison’s disease in this situation.

Addison’s disease is a condition that requires patients to undergo both glucocorticoid and mineralocorticoid replacement therapy. This treatment usually involves taking a combination of hydrocortisone and fludrocortisone. Hydrocortisone is typically given in 2 or 3 divided doses, with patients requiring 20-30 mg per day, mostly in the first half of the day. Patient education is crucial, and it is essential to emphasize the importance of not missing glucocorticoid doses. Additionally, patients should consider wearing MedicAlert bracelets and steroid cards, and they should be provided with hydrocortisone for injection with needles and syringes to treat an adrenal crisis.

During an intercurrent illness, it is crucial to manage the glucocorticoid dose properly. In simple terms, the glucocorticoid dose should be doubled, while the fludrocortisone dose should remain the same. The Addison’s Clinical Advisory Panel has produced guidelines that detail specific scenarios, and patients should refer to these guidelines for more information. It is essential to discuss how to adjust the glucocorticoid dose during an intercurrent illness with a healthcare professional. Proper management of Addison’s disease is crucial to ensure that patients can lead healthy and fulfilling lives.

Comparison of Crohn’s Disease and Ulcerative Colitis

Crohn’s disease and ulcerative colitis are two types of inflammatory bowel disease that affect the gastrointestinal tract. Crohn’s disease can occur anywhere along the GI tract, while ulcerative colitis typically only affects the large intestine.

One characteristic of Crohn’s disease is the presence of skip lesions, or areas of inflammation discontinuity. The colon wall may also appear thickened and have a cobblestone appearance. In contrast, ulcerative colitis shows continuous inflammation in affected areas, with a thinner colon wall and ulcers limited to the mucous lining of the large intestine.

Both diseases can cause rectal bleeding, but it is more common in ulcerative colitis. Other symptoms of ulcerative colitis include frequent stools and mucus discharge from the rectum, while Crohn’s disease often presents with prolonged diarrhea and abdominal pain.

Pseudopolyps, or benign lesions originating from the mucosa, can occur in both diseases but are more prevalent in ulcerative colitis. Crypt abscess formation, characterized by intense infiltration of the mucosa and submucosa with neutrophils and crypt abscesses, is a hallmark of ulcerative colitis.

Management of these diseases includes medical therapy, endoscopy, and surgery for complications such as bleeding or obstruction. Understanding the differences between Crohn’s disease and ulcerative colitis is crucial for proper diagnosis and treatment.

Diagnosing Gastrointestinal Conditions through Biopsy Findings

Biopsy findings play a crucial role in diagnosing various gastrointestinal conditions. However, some conditions require additional proof to confirm the diagnosis. Here are some examples:

Coeliac disease: Biopsy findings may show changes in the small intestine, but they are non-specific. Positive serology for anti-endomysial or anti-gliadin antibodies is needed for confirmation.

Abetalipoproteinemia: This condition can be diagnosed on biopsy findings alone. Clear enterocytes due to lipid accumulation are characteristic.

Intestinal lymphangiectasia: Biopsy findings alone can diagnose primary intestinal lymphangiectasia, which is evidenced by the dilatation of lymphatics of the intestinal mucosa without any evidence of inflammation.

Mycobacterium avium (M avium) infection: Foamy macrophages containing numerous acid-fast bacilli are characteristic of M avium infection and can be diagnosed through biopsy findings alone.

Whipple’s disease: Biopsy findings alone can diagnose Whipple’s disease, which is characterised by swollen macrophages containing numerous periodic acid Schiff (PAS) positive granules due to the glycogen content of bacterial cell walls.

Differential Diagnosis for Abdominal Pain: Chronic Mesenteric Ischaemia, Chronic Pancreatitis, Diverticulitis, Gastric Cancer, and Acute Mesenteric Ischaemic Embolism

Abdominal pain is a common presenting symptom in clinical practice, and it can be caused by a variety of conditions. In this article, we will discuss the differential diagnosis for abdominal pain, including chronic mesenteric ischaemia (CMI), chronic pancreatitis, diverticulitis, gastric cancer, and acute mesenteric ischaemic embolism.

CMI usually results from atherosclerotic disease of two or more mesenteric vessels, while chronic pancreatitis is characterised by a continuing, chronic, inflammatory process of the pancreas. Diverticulitis is an inflammation of one or more diverticula, while gastric cancer is the third most common cause of cancer-related death in the world. Acute mesenteric ischaemic embolism is characterised by pain that is disproportionate to physical examination findings.

Each condition has its own unique set of symptoms and clinical presentation. By understanding the differential diagnosis for abdominal pain, clinicians can make an accurate diagnosis and provide appropriate treatment for their patients.

Treatment Options for Helicobacter pylori Infection

Helicobacter pylori is a common bacterial infection that can cause dyspepsia and gastro-oesophageal reflux disease (GORD). There are several treatment options available for patients who test positive for H. pylori.

One option is a 7-day course of a proton pump inhibitor (PPI), amoxicillin, and either clarithromycin or metronidazole. This should be followed by a PPI for 4-8 weeks. Patients who are allergic to penicillin and have had previous exposure to clarithromycin should be offered a 7-day course of a PPI, bismuth, metronidazole, and tetracycline.

Long-term PPI and dietary advice alone will not eradicate H. pylori. If symptoms return after initial care strategies for dyspepsia, step down PPI therapy to the lowest dose needed to control symptoms. Patients with GORD should be offered full-dose PPI.

It is important to consult the British National Formulary (BNF) for appropriate doses of each drug, as they may vary. Sucralfate has no role in the eradication of H. pylori.

The appropriate surgical procedure for a patient with rectal cancer on the anal verge is abdominoperineal excision of the rectum. This procedure involves the removal of the anus, rectum, and a section of the sigmoid colon. Symptoms of rectal cancer include blood mixed with stools, changes in bowel habits, and copious mucus in stools. Haemorrhoidectomy is not the correct choice for this patient as the diagnosis is unlike. High anterior resection is used for upper rectal tumours, while low anterior resection is used for low rectal tumours, but not for anal verge tumours. Rubber band ligation is used to treat haemorrhoids in outpatient clinics, which is not the diagnosis for this patient.

Colorectal cancer is typically diagnosed through CT scans and colonoscopies or CT colonography. Patients with tumors below the peritoneal reflection should also undergo MRI to evaluate their mesorectum. Once staging is complete, a treatment plan is formulated by a dedicated colorectal MDT meeting.

For colon cancer, surgery is the primary treatment option, with resectional surgery being the only cure. The procedure is tailored to the patient and tumor location, with lymphatic chains being resected based on arterial supply. Anastomosis is the preferred method of restoring continuity, but in some cases, an end stoma may be necessary. Chemotherapy is often offered to patients with risk factors for disease recurrence.

Rectal cancer management differs from colon cancer due to the rectum’s anatomical location. Tumors can be surgically resected with either an anterior resection or an abdomino-perineal excision of rectum (APER). A meticulous dissection of the mesorectal fat and lymph nodes is integral to the procedure. Neoadjuvant radiotherapy is often offered to patients prior to resectional surgery, and those with obstructing rectal cancer should have a defunctioning loop colostomy.

Segmental resections based on blood supply and lymphatic drainage are the primary operations for cancer. The type of resection and anastomosis depend on the site of cancer. In emergency situations where the bowel has perforated, an end colostomy is often safer. Left-sided resections are more risky, but ileo-colic anastomoses are relatively safe even in the emergency setting and do not need to be defunctioned.

When a patient experiences progressive dysphagia along with weight loss, it is important to investigate for possible oesophageal carcinoma as this is a common characteristic. Laryngeal nerve damage can also cause hoarseness in patients with this type of cancer. Although achalasia may present with similar symptoms, patients typically have difficulty swallowing both solids and liquids equally and may experience intermittent regurgitation of food. On the other hand, patients with oesophageal spasm usually experience pain when swallowing.

Oesophageal Cancer: Types, Risk Factors, Features, Diagnosis, and Treatment

Oesophageal cancer used to be mostly squamous cell carcinoma, but adenocarcinoma is now becoming more common, especially in patients with a history of gastro-oesophageal reflux disease (GORD) or Barrett’s. Adenocarcinoma is usually located near the gastroesophageal junction, while squamous cell tumours are found in the upper two-thirds of the oesophagus.

Risk factors for adenocarcinoma include GORD, Barrett’s oesophagus, smoking, achalasia, and obesity. Squamous cell cancer is more common in the developing world and is associated with smoking, alcohol, achalasia, Plummer-Vinson syndrome, and diets rich in nitrosamines.

The most common presenting symptom for both types of oesophageal cancer is dysphagia, followed by anorexia and weight loss. Other possible features include odynophagia, hoarseness, melaena, vomiting, and cough.

Diagnosis is done through upper GI endoscopy with biopsy, endoscopic ultrasound for locoregional staging, CT scanning for initial staging, and FDG-PET CT for detecting occult metastases. Laparoscopy may also be performed to detect occult peritoneal disease.

Operable disease is best managed by surgical resection, with the most common procedure being an Ivor-Lewis type oesophagectomy. However, the biggest surgical challenge is anastomotic leak, which can result in mediastinitis. Adjuvant chemotherapy may also be used in many patients.

Overall, oesophageal cancer is a serious condition that requires prompt diagnosis and treatment. Understanding the types, risk factors, features, diagnosis, and treatment options can help patients and healthcare providers make informed decisions about managing this disease.

Lifestyle Advice for Patients with Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic inflammatory process that can affect any part of the gastrointestinal tract. Patients with IBD may experience symptoms such as diarrhoea, abdominal pain, and bleeding. Here are some lifestyle advice for patients with IBD:

Stop smoking: Research suggests that smoking can make Crohn’s disease worse. Smokers with Crohn’s disease have more severe symptoms and complications, require more medication, and are more likely to need surgery.

Eat a balanced diet: Patients with IBD may need to be careful about the amount and type of fibre in their diet. During flare-ups, it may be helpful to reduce the amount of insoluble fibre consumed, but, once the flare-up is over, it is important to increase fibre intake again.

Avoid alcohol: Although there is no evidence that alcohol consumption worsens IBD symptoms, alcohol can affect the lining of the gastrointestinal tract and interact with certain medications.

Quit smoking: Although smoking may delay or even prevent ulcerative colitis, the health risks of smoking outweigh any benefits seen in UC, and strongly discourage smoking in everyone, whether or not they have IBD.

Consider probiotics: The role of probiotics in IBD is not fully understood, but their use can be discussed with a General Practitioner or dietitian. More research is needed on their general effectiveness.

Primary Biliary Cholangitis: A Chronic Liver Disorder

Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a chronic liver disorder that is commonly observed in middle-aged women. The exact cause of this condition is not yet fully understood, but it is believed to be an autoimmune disease. The disease is characterized by the progressive damage of interlobular bile ducts due to chronic inflammation, leading to cholestasis and eventually cirrhosis. The most common symptom of primary biliary cholangitis is itching in middle-aged women.

This condition is often associated with other autoimmune diseases such as Sjogren’s syndrome, rheumatoid arthritis, systemic sclerosis, and thyroid disease. Early symptoms of primary biliary cholangitis may be asymptomatic or may include fatigue, pruritus, and cholestatic jaundice. Late symptoms may progress to liver failure. Diagnosis of primary biliary cholangitis involves immunology tests such as anti-mitochondrial antibodies (AMA) M2 subtype and smooth muscle antibodies, as well as imaging tests to exclude an extrahepatic biliary obstruction.

The first-line treatment for primary biliary cholangitis is ursodeoxycholic acid, which slows down the progression of the disease and improves symptoms. Cholestyramine is used to alleviate pruritus, and fat-soluble vitamin supplementation is recommended. In severe cases, liver transplantation may be necessary, especially if bilirubin levels exceed 100. However, recurrence in the graft can occur, but it is not usually a problem. Complications of primary biliary cholangitis include cirrhosis, portal hypertension, ascites, variceal hemorrhage, osteomalacia, osteoporosis, and an increased risk of hepatocellular carcinoma.

Bone marrow suppression, which can be fatal, is a potential risk associated with the use of azathioprine as a second-line treatment for Crohn’s disease. Budesonide, a corticosteroid medication primarily used for asthma prevention, may be considered as a second-line option for inducing remission in Crohn’s patients. Mesalazine, which acts locally on the colon’s mucous membrane and has various anti-inflammatory effects, is less effective than glucocorticoids but can be used as a second-line option to induce remission. Methotrexate, a folate derivative that inhibits enzymes responsible for nucleotide synthesis, is the second-line medication used to maintain remission in Crohn’s patients. However, in this case, there is no indication to use second-line management instead of first-line treatment.

Managing Crohn’s Disease: Guidelines and Treatment Options

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. To manage this condition, the National Institute for Health and Care Excellence (NICE) has published guidelines that provide recommendations for inducing and maintaining remission, as well as treating complications. One of the most important steps in managing Crohn’s disease is to advise patients to quit smoking, as this can worsen the condition. Additionally, some medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and the combined oral contraceptive pill, may increase the risk of relapse, although the evidence is not conclusive.

To induce remission, glucocorticoids are often used, either orally, topically, or intravenously. Budesonide is an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about the side effects of steroids. Second-line treatments for inducing remission include 5-ASA drugs like mesalazine, as well as azathioprine or mercaptopurine, which may be used in combination with other medications. Methotrexate is another option. Infliximab is useful for refractory disease and fistulating Crohn’s, and patients may continue on azathioprine or methotrexate.

To maintain remission, stopping smoking is a priority, and azathioprine or mercaptopurine is used first-line. TPMT activity should be assessed before starting these medications. Methotrexate is used second-line. Surgery may be necessary for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Perianal fistulae and abscesses require specific treatments, such as oral metronidazole, anti-TNF agents like infliximab, or a draining seton. By following these guidelines and treatment options, patients with Crohn’s disease can better manage their condition and improve their quality of life.

When investigating suspected perianal fistulae in patients with Crohn’s disease, MRI is the preferred imaging modality. This is because an MRI can accurately map out the extent and track of the fistula, as well as identify any associated abscesses or other fistulas. As perianal fistulas are a soft tissue pathology, an MRI pelvis is the most effective way to visualize them. Barium enema is not reliable for imaging small structures like fistulas, while CT pelvis may potentially identify fistulas but is less sensitive and accurate than MRI. Endo-anal ultrasound may be used for some perianal fistulas, but given the likelihood of complex fistulas in Crohn’s disease, MRI is the preferred option. Additionally, MRI is preferable in adults of reproductive age to avoid unnecessary radiation exposure to the reproductive organs.

Managing Crohn’s Disease: Guidelines and Treatment Options

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. To manage this condition, the National Institute for Health and Care Excellence (NICE) has published guidelines that provide recommendations for inducing and maintaining remission, as well as treating complications. One of the most important steps in managing Crohn’s disease is to advise patients to quit smoking, as this can worsen the condition. Additionally, some medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and the combined oral contraceptive pill, may increase the risk of relapse, although the evidence is not conclusive.

To induce remission, glucocorticoids are often used, either orally, topically, or intravenously. Budesonide is an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about the side effects of steroids. Second-line treatments for inducing remission include 5-ASA drugs like mesalazine, as well as azathioprine or mercaptopurine, which may be used in combination with other medications. Methotrexate is another option. Infliximab is useful for refractory disease and fistulating Crohn’s, and patients may continue on azathioprine or methotrexate.

To maintain remission, stopping smoking is a priority, and azathioprine or mercaptopurine is used first-line. TPMT activity should be assessed before starting these medications. Methotrexate is used second-line. Surgery may be necessary for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Perianal fistulae and abscesses require specific treatments, such as oral metronidazole, anti-TNF agents like infliximab, or a draining seton. By following these guidelines and treatment options, patients with Crohn’s disease can better manage their condition and improve their quality of life.

The latest recommendations state that individuals should limit their alcohol consumption to no more than 14 units per week, regardless of gender. Additionally, it is suggested that individuals should spread out their drinking over a minimum of three days if they regularly consume 14 units per week.

Alcohol consumption guidelines were revised in 2016 by the Chief Medical Officer, based on recommendations from an expert group report. The most significant change was a reduction in the recommended maximum number of units of alcohol for men from 21 to 14, aligning with the guidelines for women. The government now advises that both men and women should not exceed 14 units of alcohol per week, and if they do, it is best to spread it evenly over three or more days. Pregnant women are advised not to drink alcohol at all, as it can cause long-term harm to the baby. One unit of alcohol is equivalent to 10 mL of pure ethanol, and the strength of a drink is determined by its alcohol by volume (ABV). Examples of one unit of alcohol include a 25ml single measure of spirits with an ABV of 40%, a third of a pint of beer with an ABV of 5-6%, and half a 175ml standard glass of red wine with an ABV of 12%. To calculate the number of units in a drink, multiply the number of millilitres by the ABV and divide by 1,000.

Chronic haemolysis and gallstone formation are present in this patient with hereditary spherocytosis. It is crucial to consider splenic rupture as a potential differential diagnosis in a patient with hereditary spherocytosis who is unwell.

Understanding Hereditary Spherocytosis

Hereditary spherocytosis is the most common hereditary haemolytic anaemia in people of northern European descent. It is an autosomal dominant defect of the red blood cell cytoskeleton, which replaces the normal biconcave disc shape with a sphere-shaped red blood cell. This condition reduces the red blood cell survival as they are destroyed by the spleen. Patients with hereditary spherocytosis may present with failure to thrive, jaundice, gallstones, splenomegaly, and aplastic crisis precipitated by parvovirus infection. The degree of haemolysis is variable, and the mean corpuscular haemoglobin concentration (MCHC) is elevated.

The diagnosis of hereditary spherocytosis is based on a family history of the condition, typical clinical features, and laboratory investigations such as spherocytes, raised MCHC, and an increase in reticulocytes. The osmotic fragility test was previously the recommended investigation of choice, but it is now deemed unreliable and is no longer recommended. If the diagnosis is equivocal, the EMA binding test and the cryohaemolysis test are recommended. For atypical presentations, electrophoresis analysis of erythrocyte membranes is the method of choice.

The management of hereditary spherocytosis involves supportive treatment during acute haemolytic crisis, including transfusion if necessary. Longer-term treatment includes folate replacement and splenectomy. It is important to note that hereditary spherocytosis differs from G6PD deficiency, which is an X-linked recessive condition that affects males of African and Mediterranean descent. The diagnostic test for G6PD deficiency involves measuring enzyme activity, while the EMA binding test is used for hereditary spherocytosis.

The elevated ferritin level can be attributed to the patient’s excessive alcohol consumption, as the typical transferrin saturation rules out iron overload as a potential cause.

Understanding Ferritin Levels in the Body

Ferritin is a protein found inside cells that binds to iron and stores it until it is needed in other parts of the body. When ferritin levels are increased, it is usually defined as being above 300 µg/L in men and postmenopausal women, and above 200 µg/L in premenopausal women. However, it is important to note that ferritin is an acute phase protein, meaning that it can be produced in higher quantities during times of inflammation. This can lead to falsely elevated results, which must be interpreted in the context of the patient’s clinical picture and other blood test results.

There are two main categories of causes for increased ferritin levels: those without iron overload (which account for around 90% of cases) and those with iron overload (which account for around 10% of cases). Causes of increased ferritin levels without iron overload include inflammation, alcohol excess, liver disease, chronic kidney disease, and malignancy. Causes of increased ferritin levels with iron overload include primary iron overload (hereditary hemochromatosis) and secondary iron overload (such as from repeated transfusions). To determine whether iron overload is present, the best test is transferrin saturation, with normal values being less than 45% in females and less than 50% in males.

On the other hand, reduced ferritin levels can indicate a deficiency in iron, which can lead to anemia. When iron and ferritin are bound together, a decrease in ferritin levels can suggest a decrease in iron levels as well. Measuring serum ferritin levels can be helpful in determining whether a low hemoglobin level and microcytosis are truly caused by an iron deficiency state.

Tests for Helicobacter pylori

There are several tests available to diagnose Helicobacter pylori infection. One of the most common tests is the urea breath test, where patients consume a drink containing carbon isotope 13 (13C) enriched urea. The urea is broken down by H. pylori urease, and after 30 minutes, the patient exhales into a glass tube. Mass spectrometry analysis calculates the amount of 13C CO2, which indicates the presence of H. pylori. However, this test should not be performed within four weeks of treatment with an antibacterial or within two weeks of an antisecretory drug.

Another test is the rapid urease test, also known as the CLO test. This involves mixing a biopsy sample with urea and a pH indicator. If there is a color change, it indicates the presence of H. pylori urease activity. Serum antibody tests can also be used, but they remain positive even after eradication. Culture of gastric biopsy can provide information on antibiotic sensitivity, while histological evaluation alone can be done through gastric biopsy. Lastly, the stool antigen test has a sensitivity of 90% and specificity of 95%.

Overall, these tests have varying levels of sensitivity and specificity, and the choice of test depends on the patient’s clinical presentation and the availability of resources.

The likelihood of having an adenoma increases with a positive result on a faecal occult blood test.

Colorectal Cancer Screening: Faecal Immunochemical Test (FIT)

Colorectal cancer is often developed from adenomatous polyps. Screening for this type of cancer has been proven to reduce mortality by 16%. The NHS offers a home-based screening programme called Faecal Immunochemical Test (FIT) to older adults. A one-off flexible sigmoidoscopy was trialled in England for people aged 55 years, but it was abandoned in 2021 due to the inability to recruit enough clinical endoscopists, which was exacerbated by the COVID-19 pandemic. The trial, partly funded by Cancer Research UK, showed promising early results, and it remains to be seen whether flexible sigmoidoscopy will be used as part of a future bowel screening programme.

Faecal Immunochemical Test (FIT) Screening:
The NHS now has a national screening programme that offers screening every two years to all men and women aged 60 to 74 years in England and 50 to 74 years in Scotland. Patients aged over 74 years may request screening. Eligible patients are sent FIT tests through the post. FIT is a type of faecal occult blood (FOB) test that uses antibodies that specifically recognise human haemoglobin (Hb). It is used to detect and quantify the amount of human blood in a single stool sample. FIT has advantages over conventional FOB tests because it only detects human haemoglobin, as opposed to animal haemoglobin ingested through diet. Only one faecal sample is needed compared to the 2-3 for conventional FOB tests. While a numerical value is generated, this is not reported to the patient or GP. Instead, they will be informed if the test is normal or abnormal. Patients with abnormal results are offered a colonoscopy. At colonoscopy, approximately 5 out of 10 patients will have a normal exam, 4 out of 10 patients will be found to have polyps that may be removed due to their premalignant potential, and 1 out of 10 patients will be found to have cancer.